Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells

De Re, V., Simula, M. P., Caggiari, L., Orzes, N., Spina, M., Da ponte, A., De Appollonia, L., Dolcetti, R., Canzonieri, V. and Cannizzaro, R. (2007) Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells. Clinical and Experimental Immunology, 148 3: 402-409. doi:10.1111/j.1365-2249.2007.03348.x


Author De Re, V.
Simula, M. P.
Caggiari, L.
Orzes, N.
Spina, M.
Da ponte, A.
De Appollonia, L.
Dolcetti, R.
Canzonieri, V.
Cannizzaro, R.
Title Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells
Journal name Clinical and Experimental Immunology   Check publisher's open access policy
ISSN 0009-9104
1365-2249
Publication date 2007-06
Sub-type Article (original research)
DOI 10.1111/j.1365-2249.2007.03348.x
Open Access Status Not yet assessed
Volume 148
Issue 3
Start page 402
End page 409
Total pages 8
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing
Language eng
Formatted abstract
An aberrant T cell population is the basis for diagnosis of refractory coeliac disease and determines the risk of enteropathy-associated T cell lymphoma. This disease is serious with a poor survival. Pathogenetic mechanisms sustaining aberrant T cell proliferation remain unknown. Recently, alemtuzumab has been proposed as a promising new approach to treat these patients. Only few single cases have been tested at present; nevertheless, in all the cases a clinical improvement was observed. However, whether intraepithelial lymphocytes have been targeted effectively by alemtuzumab is still debated. This study reports, using two-dimensional difference gel electrophoresis (2D DIGE), hyperexpressed proteins associated specifically with aberrant T cells found in a patient with coeliac disease by comparison of the protein expression of this sample with that of patients with coeliac disease and polyclonal T cells or with control subjects. The data demonstrated a significantly higher expression of IgM, apolipoprotein C-III and Charcot-Leyden crystal proteins in a duodenal biopsy specimen of the patient with clonal T cells compared with that of other patients. These preliminary results allow hypothesizing different clinical effects of alemtuzumab in patients with coeliac disease and aberrant T cell proliferation, because as well as the probable effect on T cells, alemtuzumab could exert its effect by acting on inflammatory associated CD52+ IgM+ B cells and eosinophil cells, known to produce IgM and Charcot-Leyden crystal proteins, that we demonstrated to be altered in this patient. The results also emphasize the possible association of apolipoprotein with aberrant T cell proliferation.
Keyword Coeliac disease
Immunology
MALDI-TOF analysis
Protein profile
T cell receptor
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 27 Nov 2015, 19:15:57 EST by System User on behalf of Learning and Research Services (UQ Library)